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Objectives: To assess the effectiveness of home-based palliative care on reducing hospital visits and 
whether HBPC lowered health care cost.  
Methods: We searched six bibliographic databases (Embase (Ovid); Cochrane Central Register of 
Controlled Trials; Medline (Ovid); PubMed; Web of Science Core Collection; and, CINAHL) until 
February 2019 and performed a narrative synthesis of our findings.  
Results: Of the 1,426 identified references, 21 articles based on 19 unique studies met our inclusion 
criteria, which involved 92,000 participants.  In both oncological and non-oncological patients, 
home-based palliative care consistently reduced the number of hospital visits and their length, as 
well as hospitalization costs and overall health care costs. Even though home-treated patients 
consumed more outpatient resources, a higher saving in the hospital costs counterbalanced this. The 
reduction in overall health care costs was most noticeable for study periods closer to death, with 
greater reductions in the last two months, last month and last two weeks of life. 
Significance of results: Stakeholders should recognize home-based palliative care as an intervention 
that decreases patient care costs at end of life and therefore health care providers should assess the 
preferences of patients nearing the end-of-life to identify those who will benefit most from home-
based palliative care. 
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As the population of the world ages (He, Goodkind, & Kowal, 2016), demand for health and social care 
is increasing, raising costs and placing ever greater burdens on national health care systems (Guzman-
Castillo et al., 2017).  
In this context, a careful evaluation of healthcare resources is crucial to deliver the most appropriate 
treatments to patients with severe chronic illnesses. Besides treatments focused on curing, patients 
with prevalent non-curative chronic conditions have a great need of care-oriented treatments, 
including palliative care (PC). Such a treatment is an approach that seeks to improve the quality of life 
of patients and their families by the prevention and alleviation of suffering through early 
identification, evaluation, and treatment of pain and other physical, psychosocial, and spiritual 
problems ("World Health Organization. WHO definition of palliative care,"). Inpatient palliative care 
effectively improves patients’ quality of life and satisfaction with their care (Gade et al., 2008) and a 
recent meta-analysis showed that palliative care lowers hospital costs for patients (May et al., 2018). 
However, inpatient palliative care is not for everyone; patients with terminal illness benefit even more 
when palliative care and other types of care are delivered to them at home. Home care reduces 
hospital visits and hospital deaths, which is associated with better quality of life for patients at the end 
of life (Zhang, Nilsson, & Prigerson, 2012). 
Effectiveness and cost-effectiveness of home-based general care has already been shown (Maru et al., 
2015; Winkler et al., 2018). A 2013 Cochrane systematic review determined the effectiveness of home-
based palliative care (HBPC) in reducing symptom burden for patients, and also pointed out that there 
was not enough literature to assess cost effectiveness. It also found that most of the literature focused 
on oncological patients (Gomes, Calanzani, Curiale, McCrone, & Higginson, 2013). Several more recent 
studies have assessed the economic impact of HBPC. To date, a comprehensive and systematic 
appraisal of the existing literature on this impact is missing.  Therefore, we conducted a systematic 
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review to 1) assess the effectiveness of HBPC on reducing hospital visits, and 2) assess whether HBPC 
lowered health care costs. 
Methods 
Literature search 
We conducted a systematic review that follows the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guideline and registered the protocol in PROSPERO (Moher, Liberati, 
Tetzlaff, Altman, & Grp, 2009). 
With the aid of an experienced medical information specialist (DK) we searched six electronic 
databases for peer-reviewed scientific literature related to cost of HBPC, with the goal of identifying 
studies published between 2013 and 11 February 2019 (date of last search). The search was done in 
Embase (Ovid); Cochrane Central Register of Controlled Trials; Medline (Ovid); PubMed; Web of 
Science Core Collection; and, CINAHL. We combined terms related to the exposure (palliative care, 
end-of-life care, ambulatory care, domiciliary care) and our outcomes (health expenditures, health 
care costs, hospitalization rate). We did not apply a language restriction. The full search strategies are 
available in the appendix (Supplementary material 1). To identify additional sources, we added a 
Google Scholar search and inspected the references of studies that qualified for full text review 
(backward searching). 
Study selection and inclusion criteria 
Two independent reviewers (VG and VF) screened all titles and abstracts and then reviewed 
potentially relevant articles based on full text. They resolved differences through discussion before 
coming to consensus. If no consensus was reached, a third independent reviewer solved discrepancies 
between the two reviewers. 
We included prospective and retrospective observational studies (case-control, or cohort) cross-
sectional studies,  and interventional studies (randomized and non-randomized) that studied an adult 
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palliative population (≥18 years old), at the end of life, with severe illness or with a disease end-stage 
and compared hospital visits or health care costs of those who received palliative care at home to 
those who received usual care. Usual care might include palliative care in the hospital, but not at 
home. We defined HBPC as palliative care that includes home visits.  
Data extraction 
We used a predesigned data collection form to extract relevant information from the selected studies 
including study design, sample size, characteristics of the study population, intervention and type of 
controls. We also extracted the outcomes each study assessed, and the correspondent measure of 
associations (e.g., hospitalization rate, mean length of stay, overall cost, inpatient cost, prevalence of 
death at home). 
Assessing the risk of bias 
Three reviewers (VG, VF and NG) independently rated study quality based on the Joanna Briggs 
Institute Critical Appraisal Tools Checklists for use in systematic reviews. The checklist has 11 items for 
cohort studies, nine items for quasi-experimental studies, and 13 items for RCTs. 
Data synthesis 
We conducted a narrative synthesis of the findings of the included studies. For each study, we 
determined if cost or utilization differed between groups, and whether the difference favored the 
intervention or the control. Initially, we sought to pool their results using a random effects meta-
analysis model. Because studies varied in duration and type of exposure, the time points of outcome 
assessment, and were conducted in different health systems, we could not pool these results. 
However, we could make a summary estimate of cost savings by calculating the percentage of costs 
reduced by the HBPC intervention for those studies that reported the difference between overall costs 
for patients with and without HBPC. Because several studies reported total costs at different time 
periods (e.g., from 6, 3, or 1 month until death) we performed two calculations: one included data 
from the period furthest from death and the other included data from the period closest to death. For 
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studies that stratified cost by groups (e.g., disease), we calculated the average cost in savings across 
the groups. 
Results 
We identified 1,426 unique references (Figure 1). Based on the title and abstract, we selected the full 
text of 30 articles for detailed evaluation; 21 of these articles, based on 19 studies, met our eligibility 
criteria and were included in this review. Figure 1 explains the reasons why the remaining nine articles 
were excluded.  
General characteristics of the included studies 
Table 1 details the characteristics of the 19 included studies, which together included data on 92,871 
people. Most of the studies (n=12) assessed health care cost and use, six assessed only health care 
use, and one assessed only health care cost. Ten studies assessed the place of death. The majority of 
the studies (n=9) included participants from the U.S., two from Italy, and the rest included participants 
from Belgium, Denmark, England, Israel, Singapore, Spain, Sweden, and Taiwan. Twelve were 
retrospective cohort studies, five were quasi-experimental studies (before-after studies), and two 
were randomized controlled trials (RCT). 
Most of the studies included both oncological and non-oncological patients (n=10) (Brian Cassel et al., 
2016; Chitnis, Georghiou, Steventon, & Bardsley, 2013; Hopp et al., 2015; Kerr et al., 2014; Lukas, Foltz, 
& Paxton, 2013; Lustbader et al., 2017; Maetens et al., 2019; Murphy, Siebert, Owens, & Doorenbos, 
2013; Pouliot, Weisse, Pratt, & DiSorbo, 2017; Sudat et al., 2018); six studies (reported in seven 
publications) included only oncological patients (Alonso-Babarro, Astray-Mochales, & ... 2013; Bentur, 
Resnizky, Balicer, & Eilat-Tsanani, 2014; Blackhall et al., 2016; Chiang & Kao, 2016; de Miguel, Rubert 
de la Piedra, Garcia Perez, Garcia Ruiz, & Alonso Babarro, 2018; Riolfi et al., 2014; Skov Benthien et 
al., 2018), two studies (reported in three publications) included only patients with heart failure 
(Brannstrom & Boman, 2014; Sahlen, Boman, & Brannstrom, 2016; Wong et al., 2013), and one study 
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included non-oncological patients (Ferroni et al., 2016). Non-oncological conditions included in the 
studies were dementia, senility, respiratory disease, liver disease, kidney disease, coronary artery 
disease, neurodegenerative disease and diabetes. 
Supplementary Tables 1-3 show the risk of bias assessment for each study. Although randomized 
controlled trials are rare within palliative care research, we found three. These studies were the 
studies at lower risk of bias. The risk within those studies mainly consisted out of non-concealment of 
the HBPC intervention.  The five quasi-experimental studies also had low risks of bias scores. The 
biggest problem with quasi-experimental studies was the lack of an independent control group as 
those studies were before-after studies. The 13 retrospective cohort studies were at higher risk of bias 
due to unclear or non-existing handling of confounding (Chiang & Kao, 2016; de Miguel et al., 2018; 
Lustbader et al., 2017). 
 
Home-based palliative care intervention 
Out of the 19 studies, 18 clearly described the intervention. The remaining one, used claim data to 
search for care codes and those patients with home hospice codes were included in the intervention 
group (Chiang & Kao, 2016). The majority of the studies (n=11) consisted of a multidisciplinary team 
that involved nurses, PC specialists, social workers, psychologists, physiotherapists, chaplains or 
other spiritual care providers. In five studies, the care in the intervention group was only provided by 
physicians and nurses, in one by palliative care specialist and heart failure specialist and in one by 
nurses and assistants (Table 1). At least six of the studies stated the availability of the assistance was 




Fourteen studies assessed hospital admission rates; two of these evaluated admissions to an intensive 
care unit (ICU) (Brian Cassel et al., 2016; Maetens et al., 2019). Most studies (n=9) compared groups 
of patients who had and did not have access to HBPC (Table 1). These studies found that the group of 
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patients with HBPC had smaller percentage of patients being hospitalized or admitted at least once to 
the ICU compared to the group without HBPC. Additionally, the group with HBPC showed a lower 
average number of hospitalizations per patient or per intervention group and lower risk of hospital 
admission. Only one study, a secondary analysis of an RCT, noted more hospital admissions in the 
intervention group, but the difference was not significant. This study’s results were derived from an 
intention-to-treat analysis in which two thirds of the patients in the control group also received the 
intervention (Skov Benthien et al., 2018). 
These results aligned with the results of the five quasi-experimental studies in which the control was 
the patient before HBPC intervention. These five studies found hospital admissions dropped after the 
HBPC service was introduced regardless when the mark before/after was chose. Four of them 
compared the hospital admissions in a symmetric way, for example, 18 months before intervention vs 
18 month after intervention (Lukas et al., 2013), or six months before vs six months after the 
intervention (Hopp et al., 2015). They found the reduction in hospital admission to be significant (Hopp 
et al., 2015; Lukas et al., 2013; Pouliot et al., 2017; Wong et al., 2013). The remaining study, which was 
the only one not assessing the outcome in a symmetric way, did not reach the stablished significance 
level (Murphy et al., 2013).   
Hospitalization length 
The length of hospital stay was assessed by nine studies. All of them found that significantly shorter 
hospital stays were significantly shorter among patients with HBPC than among controls. One study 
of more than 7,900 oncological and non-oncological patients compared the length of hospital stay 
over the last three months of life in patients receiving HBPC compared to their matched controls. They 
found a significant reduction in length of hospital stay in the patient group receiving HBPC. They found 
that the number of days in hospital during the last three, two, and one months of life was significantly 
reduced; the difference was greater than 30% (Sudat et al., 2018). Another study of more than 2,000 
non-oncological participants assessed the risk of prolonged hospitalization at the end of life, defined 
as a stay that exceeds the 75th percentile of the stay that occurred during the last month of life. The 
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authors found that there was a dose–response relationship: risk decreased with an increase in the 
number of HBPC visits per week (Ferroni et al., 2016) (Table 2). 
Emergency Department admission 
Seven studies assessed emergency department admission; five found that patients with HBPC used 
significantly less ED, measured as the percentage of patients admitted at least once to ED or as risk of 
an ED admission. One large study of over 59,000 oncological patients found that only 12% of the 
patients with HBPC had at least one ED admission vs. 35% of the matched controls (Chitnis et al., 
2013). Another large study of more than 17,000 oncological and non-oncological patients found that 
the risk of ED admission during the last two weeks of life was twice as high for those without HBPC 
than those with HBPC (Maetens et al., 2019). The remaining two studies found no difference or an 
insignificantly lower difference in ED use (Bentur et al., 2014; Murphy et al., 2013) (Table 2). 
Health care cost 
Average overall cost 
There were 11 studies assessing this outcome. Of them, the majority of the studies (n=10) compared 
a group of patients who had access to HBPC to patients without access. The remaining study used the 
same patients as controls (before introduction of HBPC) and as the intervention group (Hopp et al., 
2015) (Table 1). The studies assessed the outcome over different periods, ranging from the last month 
to the last year of life (Table 3). Seven studies included both oncological and non-oncological patients 
(Brian Cassel et al., 2016; Chitnis et al., 2013; Hopp et al., 2015; Kerr et al., 2014; Lustbader et al., 2017; 
Maetens et al., 2019; Sudat et al., 2018), three only oncological patients (Bentur et al., 2014; Blackhall 
et al., 2016; Chiang & Kao, 2016), and one only patients with heart failure (Sahlen et al., 2016). 
Of the 11 studies that assessed overall cost in health, six studies specified that they had taken into 
account the costs of the intervention itself while the other five did not specify whether they had 
included these costs or not. When taking into account all the articles that evaluated overall cost in 
health, regardless of whether or not they included the costs of the intervention itself, average total 
health care cost per patient was lower for those with access to HBPC than for controls.  
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Studies that assessed the outcome at different points in time found that the cost reduction was most 
noticeable closer to death, with the greatest reductions in the last two months, one month, and two 
weeks of life (Blackhall et al., 2016; Kerr et al., 2014; Lustbader et al., 2017). Including all 11 studies 
assessing average overall cost, the intervention saved 36.3% (IQR: 28.8%-51.8%) when taking into 
account the costs reported at the period closest to death. Similar results were obtained when taking 
into account for the analysis the cost reported at the period most distant to death, with a saving in 
the overall health cost of 35.7% (IQR: 26.2%-36.8%) in favor of the HBPC group. 
The largest study, a retrospective cohort that included more than 29,500 oncological and non-
oncological patients who had been under HBPC and had died matched them 1:1 to patients without 
HBPC who died during the same period, had similar demographic and clinical characteristics, and 
similar prior hospital use; average overall cost per person for those under HBPC was significantly lower 
than the cost for the controls (Chitnis et al., 2013). 
Those six studies that took into account the cost of the intervention program(Brian Cassel et al., 2016; 
Kerr et al., 2014; Lustbader et al., 2017; Maetens et al., 2019; Sahlen et al., 2016; Sudat et al., 2018), 
also found a reduction in average total health care. Of them, three large studies summing up more 
than 27,000, found costs to be lower among patients with HBPC in the last three, two, and one months 
of life (Brian Cassel et al., 2016; Maetens et al., 2019; Sudat et al., 2018). One of these studies 
presented results by patient diagnosis and found that cost reductions were significant across all 
conditions they included (cancer, COPD, heart failure and dementia) (Brian Cassel et al., 2016). 
Another study taking into account the cost of the intervention program analyzed the average overall 
cost in different periods (Kerr et al., 2014). This study showed that patients with HBPC had significantly 
lower average overall costs compared to patients without HBPC during the last three months, last 
month, and last two weeks of life. When they analyzed these same costs during the last six months 
and last two years of life, the costs were equal between both groups. Another study, found HBPC 
lowered cost over the last year of life and significantly lowered cost over the last six months, last three 
11 
 
months, and last month of life (Lustbader et al., 2017). Outpatient cost and staff cost were generally 
equal or higher for patients with HBPC than for patients without HBPC (Kerr et al., 2014; Maetens et 
al., 2019; Sahlen et al., 2016), so the drop in overall health care costs was a result of significantly lower 
inpatient cost among patients with HBPC. 
Hospitalization cost 
Seven studies assessed costs generated by hospitalizations, and all found that inpatient costs were 
lower in patients who received palliative home care. One RCT conducted among patients with heart 
failure with six months follow-up found that inpatient cost in the group with access to HBPC was at 
least three times less than the cost in the control arm (Sahlen et al., 2016). Two large retrospective 
cohorts with a combined total of over 25,000 participants, used matched analysis to adjust for 
confounders and found significantly lower hospitalization cost among patients with HBPC during the 
last three months, two months, one month, and 2 weeks of patients’ life (Maetens et al., 2019; Sudat 
et al., 2018) (Table 2). 
Other costs 
Two studies assessed outpatient cost. Of them, one included the home care cost in the outpatient cost 
and found higher values for those with access to HBPC (Maetens et al., 2019). The other one reported 
no difference in cost at six months before death and lower cost in the lasts three months, two months 
and two weeks of life among patient with access to HBPC. This last study, additionally reported costs 
derived from visits to the emergency department and found no difference in none of the time periods 
(Kerr et al., 2014) (Table 2). 
Additional outcomes 
Place of death 
Among the ten studies reporting this outcome, six reported percentage of deaths at home. Among 
this studies, the percentage of patients who died at home was at least twice as high among those 
who had access to HBPC compared to those who did not, with a ratio ranging from 2.2 to 6.8 (Bentur 
et al., 2014; Chiang & Kao, 2016; Chitnis et al., 2013; de Miguel et al., 2018; Maetens et al., 2019; 
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Riolfi et al., 2014). Three studies reported the percentage of patients who died outside the hospital, 
including home and health care facilities such as hospices (Blackhall et al., 2016; Brian Cassel et al., 
2016; Sudat et al., 2018). Their results were consistent, with higher amount of patients dying outside 
hospitals in the HBPC group. Finally, the remaining study reported the risk of hospital in each group 
and found that relative risk of hospital death decreased with a dose–response relationship, 
according to the number of homecare visits per week performed in the last months of life (Ferroni et 
al., 2016).  
Discussion 
Main findings 
We found HBPC was consistently effective on reducing the number and length of hospital visits, 
regardless of a patient’s oncological status. The number of emergency department visits was lower or 
equal to the number in the control group. HBPC consistently reduced health care costs by reducing 
costly hospital stays, even though home-treated patients consumed more outpatient resources. 
Since the studies designed their interventions differently and were implemented in widely different 
health systems, they were too heterogeneous to allow us to conduct a meta-analysis so we could not 
generate a pooled estimate cost saving. Despite their heterogeneity, their results consistently 
demonstrate that HBPC reduced costs.  
This review found cost reductions were highest in studies that assessed the outcome closer to death 
possibly because the number of hospitalizations increase as patients near death, and with it the 
number of hospital deaths (Alonso-Babarro et al., 2013; Bentur et al., 2014; Blackhall et al., 2016; 
Chiang & Kao, 2016; Chitnis et al., 2013; de Miguel et al., 2018; Maetens et al., 2019; Riolfi et al., 2014). 
The average number of hospitalizations increase when the patients nears death, because chronic 
diseases progress, symptoms worsen and standard (home) care is overburdened. Additionally, when 
a patient is hospitalized in a period close to death, the chances of dying in the hospital increase which 
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can be showed to be much more expensive than dying in another setting. Using data from Medicaid, 
data analysts reported that dying in hospital is seven times more expensive than dying at home 
(Solutions, 2016).  
Applicability of evidence 
All the studies we included were carried out in high income countries where the cost of hospitalization 
is higher than it is in middle- and low-income countries ("World Health Organization. Public Spending 
on Health: A Closer Look at Global Trend," 2018), so our results may not be generalizable to those 
countries. To improve the applicability of our evidence, we provided the results of the savings in the 
average overall health costs as percentages, instead of net decrease in costs. However, the results 
from our systematic review should be taken with caution before generalization.  
Limitations 
The studies we included did not aggregate the total cost of health care. They did not include out-of-
pocket expenses or other informal costs of care like the drop in household income when family 
members reduce their working hours to help care for a patient at home.  These costs are difficult to 
measure but informal care has shown to account for a high proportion of costs during the last year of 
life, highlighting the important role of informal caregivers in PC (Brick et al., 2017). There is a risk that 
HPBC reduced overall health care costs less than they appeared to, since they may have shifted costs 
from the system to patients and their caregivers, and thus rendered those costs invisible. 
As others also report (Brereton et al., 2017) we were limited by the fact that study authors did not 
clearly describe their interventions, which meant we could draw only general conclusions. For 
example, most authors did not clearly define the precise content of HBPC or describe patient diagnosis 
and any associated need for intensive and specialist care in hospitals, although these influence the 
hospital admission rate. We could only focus on cost and easily measurable effect outcomes like 
hospital utilization, but did not have enough comparable information to include important 
effectiveness outcomes like quality of death and the burden imposed on family caregivers.  
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Studies were generally of good quality but because few clearly reported the exposure there is a risk 
of non-differential misclassification, which could have led us to underestimate the effect. Additionally, 
given that most studies were observational, despite having used different strategies to control for 
confounders, there may still be residual confounding introducing bias into the results. 
Despite the heterogeneity of interventions and study design (Table 1), results were consistent across 
studies, especially for health care cost outcome, but there was some inconsistency in findings about 
use of health care. Skov et al.’s study, a secondary analysis of an RCT that assessed hospital admissions 
as outcome, found no difference between those randomized to specialized PC at home and those in 
the control arm (usual care including referral to specialized PC at home on demand); 66% of patients 
assigned to the control group received specialized PC at home (Skov Benthien et al., 2018).  Bentur et 
al.’s study was also problematic, since patients in the reference group also received home-base care 
as part of usual community care (Bentur et al., 2014). 
Implications 
The ethical argument for HBPC is strong for patients with a marked prognosis decline who want to 
remain at home. Our study bolsters that ethical argument with evidence that HBPC reduces health 
care system costs. 
When analyzing the cost-effectiveness of a new intervention, results are divided in into four 
quadrants. If a new intervention is less effective and more expensive (upper left quadrant), it ought 
to be discarded. If it is more effective but also more expensive (upper right quadrant) or less 
effective and cheaper (lower left quadrant) it warrants discussion. If it is cheaper and more effective 
(lower right quadrant), it is dominant and should be implemented. Therefore, from an economic 
perspective, our finding that HBPC decreases hospital visits while decreases costs suggests that, 
when properly analyzed in a cost effectiveness analysis, the home-based approach may be a 
dominant technology when compared to the traditional care (Petrou & Gray, 2011). However, the 
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studies identified did not report classic cost-effectiveness metrics such as the incremental cost-
effectiveness ratio (ICER). Therefore, we could not perform cost-effectiveness analysis.  
HBPC should be available to all patients in a recognizable end-of-life phase, e.g., with marked 
progressive decline, who desire to remain at home and die there. Further research would be 
necessary to determine which specific type of patient benefits the most from HBPC and has the 
highest impact on reducing health care cost. Our findings apply at the population level, but patients 
must be managed individually, taking into account the complexity of their underlying pathology to 
determine if patients with complex conditions (e.g., polymorbid patients) will benefit most from 
HBPC or in-hospital management. We thus recommend linking HBPC programs to a hospital PC 
program in case referral is necessary. In addition, reducing hospital utilization at the end of life 
should be a goal for health care planners only if access to quality home care at the end of life is 
guaranteed. The main objective should not be where to die, but how. 
Conclusion 
Our systematic review provides clear and homogenous evidence that home-based palliative care 
reduces overall end-of-life health care costs by reducing the number of hospitalizations in the last 
months of life, and thus the number of in-hospital deaths. Therefore, stakeholders should recognize 
HBPC as an intervention that decreases patient care costs at end of life and health care providers 
should assess the preferences of patients nearing the end-of-life to identify those who will benefit 
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